QURE
uniQure N.V. NASDAQ Listed Feb 5, 2014$46.70
-3.04%
vs $48.16
Mkt Cap $2.9B
52w Low $8.73
60.5% of range
52w High $71.50
50d MA $23.52
200d MA $27.38
P/E (TTM)
-13.9x
EV/EBITDA
—
P/B
13.5x
Debt/Equity
2.7x
ROE
-100.0%
P/FCF
-15.6x
RSI (14)
81.90
ATR (14)
$2.26
Beta
0.75
50d MA
$23.52
200d MA
$27.38
Avg Volume
2.4M
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Paasheuvelweg 25a · Amsterdam 1105 BP · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | BMO | -0.93 | -0.56 | +39.8% | 10.50 | -12.7% | -14.0% | +0.0% | +0.1% | +17.8% | +34.0% | — |
| Nov 10, 2025 | BMO | -0.85 | -1.38 | -62.4% | 26.15 | +1.3% | +17.9% | +0.0% | -2.3% | +0.7% | -1.5% | — |
| Jul 29, 2025 | BMO | -0.89 | -0.69 | +22.5% | 13.68 | +8.6% | +5.7% | +0.0% | -3.7% | -1.6% | +0.5% | — |
| May 9, 2025 | BMO | -1.07 | -0.82 | +23.4% | 12.79 | -0.2% | +2.8% | +0.0% | -2.6% | -1.2% | +4.7% | — |
| Feb 27, 2025 | BMO | -0.60 | -1.50 | -150.0% | 12.07 | -5.1% | +8.9% | +0.0% | -17.1% | +3.9% | +6.7% | — |
| Nov 5, 2024 | BMO | -1.12 | -0.91 | +18.8% | 6.06 | +1.5% | +18.2% | +0.0% | +3.8% | +4.8% | -1.7% | — |
| Aug 1, 2024 | BMO | -1.24 | -1.16 | +6.5% | 7.48 | -0.7% | -2.3% | +0.0% | +3.7% | -0.3% | -5.8% | — |
| May 7, 2024 | BMO | -1.31 | -1.36 | -3.8% | 4.82 | -1.5% | +1.5% | +0.0% | +3.7% | -3.0% | -0.8% | — |
| Feb 28, 2024 | BMO | -1.54 | -1.53 | +0.6% | 6.69 | -8.5% | -14.1% | +0.0% | -2.8% | -7.7% | -2.3% | — |
| Nov 7, 2023 | BMO | -1.49 | -1.88 | -26.2% | 6.88 | +3.1% | -5.4% | +0.0% | -4.0% | -3.0% | -1.0% | — |
| Aug 1, 2023 | BMO | 2.97 | -1.44 | -148.5% | 10.62 | -2.3% | -5.3% | +0.0% | -4.0% | -2.5% | -5.3% | — |
| May 9, 2023 | BMO | -1.02 | -1.63 | -59.8% | 21.79 | +0.9% | +1.9% | +0.0% | -0.2% | -1.2% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 18 | Barclays | Upgrade | Equal Weight → Overweight | $65 | — | — | — | — | — | — | — | — |
| Jun 17 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $61 | $26.99 | $43.55 | +61.4% | +78.4% | — | — | — | — |
| Apr 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $17.58 | $17.50 | -0.5% | +2.6% | -3.3% | +1.9% | -1.3% | +2.8% |
| Mar 23 | Barclays | Maintains | Equal Weight → Equal Weight | — | $16.09 | $16.06 | -0.2% | -1.1% | -4.6% | +7.8% | -4.6% | -5.3% |
| Mar 11 | Mizuho | Upgrade | Neutral → Outperform | — | $18.26 | $18.51 | +1.4% | -3.8% | -3.5% | -8.3% | +2.6% | -2.0% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.99 | $17.96 | -0.2% | +1.5% | -3.8% | -3.5% | -8.3% | +2.6% |
| Mar 9 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $14.27 | $18.02 | +26.3% | +26.1% | +1.5% | -3.8% | -3.5% | -8.3% |
| Mar 9 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $14.27 | $18.02 | +26.3% | +26.1% | +1.5% | -3.8% | -3.5% | -8.3% |
| Mar 9 | Chardan Capital | Maintains | Buy → Buy | — | $14.27 | $18.02 | +26.3% | +26.1% | +1.5% | -3.8% | -3.5% | -8.3% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.50 | $9.17 | -12.7% | -14.0% | +0.1% | +17.8% | +34.0% | +26.1% |
| Mar 3 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $10.50 | $9.17 | -12.7% | -14.0% | +0.1% | +17.8% | +34.0% | +26.1% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $10.50 | $9.17 | -12.7% | -14.0% | +0.1% | +17.8% | +34.0% | +26.1% |
| Mar 3 | Mizuho | Downgrade | Outperform → Neutral | — | $10.50 | $9.17 | -12.7% | -14.0% | +0.1% | +17.8% | +34.0% | +26.1% |
| Mar 2 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $15.63 | $9.19 | -41.2% | -32.8% | -14.0% | +0.1% | +17.8% | +34.0% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.05 | $25.55 | -1.9% | -5.1% | -2.4% | -7.2% | -8.4% | +6.1% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $20.14 | $20.00 | -0.7% | -1.9% | -1.2% | +4.7% | +7.1% | +5.2% |
| Dec 9 | Mizuho | Maintains | Outperform → Outperform | — | $21.77 | $21.62 | -0.7% | -4.5% | -3.1% | -1.9% | -1.2% | +4.7% |
| Dec 4 | Chardan Capital | Maintains | Buy → Buy | — | $25.48 | $21.25 | -16.6% | -10.8% | -6.2% | +2.1% | -4.5% | -3.1% |
| Nov 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $30.84 | $29.86 | -3.2% | -2.3% | +0.7% | -1.5% | +1.5% | -2.0% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $26.15 | $26.49 | +1.3% | +17.9% | -2.3% | +0.7% | -1.5% | +1.5% |
| Nov 10 | Leerink Partners | Maintains | Outperform → Outperform | — | $27.79 | $26.50 | -4.6% | -5.9% | +17.9% | -2.3% | +0.7% | -1.5% |
| Nov 4 | William Blair | Downgrade | Outperform → Market Perform | — | $34.29 | $30.81 | -10.1% | -11.2% | -14.4% | +5.6% | +1.0% | -5.9% |
| Nov 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $34.29 | $30.81 | -10.1% | -11.2% | -14.4% | +5.6% | +1.0% | -5.9% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $34.29 | $30.81 | -10.1% | -11.2% | -14.4% | +5.6% | +1.0% | -5.9% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.29 | $30.81 | -10.1% | -11.2% | -14.4% | +5.6% | +1.0% | -5.9% |
| Nov 3 | Chardan Capital | Maintains | Buy → Buy | — | $67.69 | $23.05 | -65.9% | -49.3% | -11.2% | -14.4% | +5.6% | +1.0% |
| Oct 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.92 | $55.55 | +1.1% | -3.7% | +9.5% | +3.5% | +6.1% | -3.3% |
| Oct 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $54.99 | $55.87 | +1.6% | -0.9% | +0.8% | -3.7% | +9.5% | +3.5% |
| Sep 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.50 | $50.43 | +6.2% | +10.8% | +3.2% | +9.4% | -1.7% | -5.8% |
| Sep 25 | Mizuho | Maintains | Outperform → Outperform | — | $47.50 | $50.43 | +6.2% | +10.8% | +3.2% | +9.4% | -1.7% | -5.8% |
| Sep 25 | Goldman Sachs | Maintains | Neutral → Neutral | — | $47.50 | $50.43 | +6.2% | +10.8% | +3.2% | +9.4% | -1.7% | -5.8% |
| Sep 25 | Guggenheim | Maintains | Buy → Buy | — | $47.50 | $50.43 | +6.2% | +10.8% | +3.2% | +9.4% | -1.7% | -5.8% |
| Sep 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $47.50 | $50.43 | +6.2% | +10.8% | +3.2% | +9.4% | -1.7% | -5.8% |
| Sep 25 | Chardan Capital | Maintains | Buy → Buy | — | $47.50 | $50.43 | +6.2% | +10.8% | +3.2% | +9.4% | -1.7% | -5.8% |
| Sep 24 | Stifel | Maintains | Buy → Buy | — | $13.66 | $39.36 | +188.1% | +247.7% | +10.8% | +3.2% | +9.4% | -1.7% |
| Sep 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $13.66 | $39.36 | +188.1% | +247.7% | +10.8% | +3.2% | +9.4% | -1.7% |
| Sep 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.66 | $39.36 | +188.1% | +247.7% | +10.8% | +3.2% | +9.4% | -1.7% |
| Sep 8 | Chardan Capital | Maintains | Buy → Buy | — | $17.95 | $18.16 | +1.2% | -2.9% | +0.3% | -0.1% | -3.1% | -2.7% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.95 | $18.16 | +1.2% | -2.9% | +0.3% | -0.1% | -3.1% | -2.7% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.73 | $17.92 | +1.1% | +1.2% | -2.9% | +0.3% | -0.1% | -3.1% |
| Aug 29 | Chardan Capital | Maintains | Buy → Buy | — | $16.26 | $16.27 | +0.1% | +0.4% | +4.2% | +2.2% | +2.0% | +1.2% |
| Jul 29 | Chardan Capital | Maintains | Buy → Buy | — | $14.98 | $14.74 | -1.6% | -8.7% | +5.7% | -3.7% | -1.6% | +0.5% |
| May 30 | Chardan Capital | Maintains | Buy → Buy | — | $14.90 | $14.77 | -0.9% | -2.9% | +0.1% | +4.6% | -1.3% | +11.0% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.04 | $15.90 | +5.7% | -0.9% | -2.9% | +0.1% | +4.6% | -1.3% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $12.79 | $12.76 | -0.2% | +2.8% | -2.6% | -1.2% | +4.7% | +3.4% |
| May 12 | Guggenheim | Maintains | Buy → Buy | — | $12.79 | $12.76 | -0.2% | +2.8% | -2.6% | -1.2% | +4.7% | +3.4% |
| May 6 | Chardan Capital | Maintains | Buy → Buy | — | $15.89 | $15.51 | -2.4% | -27.8% | -12.4% | +21.8% | +4.4% | +2.8% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $12.94 | -0.5% | +2.2% | +8.3% | +0.0% | -0.9% | -0.6% |
| Apr 1 | Chardan Capital | Maintains | Buy → Buy | — | $10.60 | $10.77 | +1.6% | -6.5% | +7.2% | -8.2% | -8.1% | -2.2% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.90 | $10.71 | -1.7% | +3.9% | +6.7% | +3.5% | -2.2% | -4.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Potts JeannetteOff | Chief Legal Officer | Sell | 5,237 | $27.67 | $145K | 133,246 | — | — |
| Jun 15, 2026 | Balachandran MadhavanDir | — | Sell | 10,000 | $27.85 | $278K | 43,254 | — | — |
| May 8, 2026 | Abi-Saab WalidOff | Chief Medical Officer | Sell | 20,000 | $25.00 | $500K | 169,669 | +0.24% | -0.96% |
| May 8, 2026 | Abi-Saab WalidOff | Chief Medical Officer | Sell | 25,000 | $25.10 | $628K | 189,669 | +0.24% | -0.96% |
8-K · 8.01
!! High
uniQure N.V. -- 8-K 8.01: Material Event / Announcement
Jun 17
8-K · 2.02
!! High
uniQure N.V. -- 8-K 2.02: Earnings Results
uniQure reported financial results via press release, with detailed operational and financial condition updates available in the attached exhibit for investor review.
May 5
8-K · 7.01
! Medium
uniQure N.V. -- 8-K 7.01: Regulation FD Disclosure
uniQure (QURE) disclosed material information via press release to comply with Regulation FD, ensuring equal public access to company announcements without prior selective disclosure to investors.
Apr 30
8-K · 7.01
! Medium
uniQure N.V. -- 8-K 7.01: Regulation FD Disclosure
uniQure announced a regulatory update on AMT-130, its investigational Huntington's disease gene therapy, potentially signaling progress toward commercialization or addressing previous regulatory concerns.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors Llc | 5,959,595 | $97M | Reduced | Mar 2026 |
| 2 | Aberdeen Group Plc | 5,306,386 | $87M | Added | Mar 2026 |
| 3 | Boxer Capital Management, Llc | 800,000 | $47M | Reduced | Sep 2025 |
| 4 | Two Sigma Investments, Lp | 2,675,871 | $44M | Added | Mar 2026 |
| 5 | Rtw Investments, Lp | 2,586,356 | $42M | Reduced | Mar 2026 |
| 6 | Jpmorgan Chase & Co | 2,837,466 | $42M | Reduced | Mar 2026 |
| 7 | Morgan Stanley | 1,433,854 | $34M | Added | Dec 2025 |
| 8 | Jennison Associates Llc | 1,371,190 | $33M | Added | Dec 2025 |
| 9 | Tyro Capital Management Llc | 1,327,858 | $32M | New | Dec 2025 |
| 10 | Fmr Llc | 1,743,808 | $29M | Reduced | Mar 2026 |
| 11 | Mpm Bioimpact Llc | 1,369,231 | $22M | Reduced | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 1,002,800 | $16M | Reduced | Mar 2026 |
| 13 | Millennium Management | 792,756 | $13M | Reduced | Mar 2026 |
| 14 | Sg Americas Securities, Llc | 776,604 | $13M | Added | Mar 2026 |
| 15 | Maverick Capital Ltd | 697,640 | $11M | Added | Mar 2026 |
| 16 | Vanguard Capital Management Llc | 694,721 | $11M | New | Mar 2026 |
| 17 | Voss Capital, Lp | 605,000 | $10M | Added | Mar 2026 |
| 18 | Ubs Group Ag | 487,838 | $8M | Reduced | Mar 2026 |
| 19 | Privium Fund Management B.v. | 486,520 | $8M | Added | Mar 2026 |
| 20 | Franklin Resources Inc | 480,866 | $8M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 19
All ↗
Valuation
Market Cap
$2.95B
Enterprise Value
$2.67B
P/E (TTM)
-13.92x
Forward P/E
—
PEG Ratio
0.23x
P/B
13.50x
P/S
166.80x
P/FCF
-15.56x
EV/EBITDA
—
Shares Out
57.5M
Financials (TTM)
Revenue
$16.1M
Net Income
-$199.0M
EBITDA
-$178.6M
Free Cash Flow
-$178.0M
Op Cash Flow
-$178.0M
EPS Basic
$-3.46
EPS Diluted
$-3.46
EPS Forward
$-3.48
Gross Margin
-2.2%
Op Margin
-1152.1%
Net Margin
-1236.0%
Balance Sheet
Total Assets
$824.9M
Total Liab.
$626.0M
Total Equity
$198.9M
Cash
$622.5M
LT Debt
$522.9M
Book Value/Sh
$3.46
Debt/Equity
2.70x
Current Ratio
10.43
Quick Ratio
10.43
Returns & Growth
ROE
-100.0%
ROA
-24.1%
ROIC
-24.2%
Rev Growth YoY
-40.6%
EPS Growth YoY
+29.7%
Price Returns
2W
+2.8%
1M
+43.0%
3M
+82.5%
6M
+3.7%
12M
+97.2%
Technicals
52W High
$71.50
52W Low
$8.73
50d MA
$23.52
200d MA
$27.38
RSI (14)
81.90
ATR (14)
$2.26
Beta
0.75
Avg Volume
2.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$36.11
High
$70.00
Low
$10.00
Median
$35.00
Data updated apr 26, 2026 9:44pm
· Source: financialmodelingprep.com